Thus, the inhibition of CD8+ T cells proliferation and activation observed upon Tanimilast treatment may be beneficial to alleviate cytotoxic hyperactivation but might be not relevant, if not contraindicated, in COVID-19 cases displaying an exhausted CD8+ T cell phenotype. This evidence concerns the gene CD8A and COVID-19.